Calcium

Calcium: A Comprehensive Reference

1. Identity and Chemical Characterization

Calcium (chemical symbol Ca; atomic number 20) is an alkaline earth metal belonging to Group 2 of the periodic table. The name "calcium" is derived from the Latin word calx, meaning lime or limestone, reflecting its historical use and abundance in these materials. As a dietary mineral and supplement, calcium is not consumed in its pure metallic form but rather as various chemical salts and compounds. Calcium is the most abundant metal and the fifth-most abundant element in the human body. Calcium does not occur naturally in the free state, but compounds of the element are widely distributed.

As calcite (calcium carbonate), it occurs on Earth in limestone, chalk, marble, dolomite, eggshells, pearls, coral, stalactites, stalagmites, and the shells of many marine animals.

Natural Sources and Dietary Forms

A wide array of natural calcium sources exist, including dairy products, such as milk, yogurt, and cheese; vegetables, such as broccoli and kale; and foods fortified with calcium, such as fruit juices, cereals, and some grains. Some nondairy foods also contain calcium, including certain vegetables (e.g., kale, broccoli, Chinese cabbage) and canned sardines and salmon with bones. In addition, some nondairy foods, such as many fruit juices, milk substitutes, tofu, and cereals, are fortified with calcium.

In Europe and North America, approximately 75% of dietary calcium is derived from milk and dairy products, with an additional 15% from vegetables and fruits, 5% from mineral water, and the rest from other foods. Bovine milk contains an average of 120 mg calcium per 100 mL.

Common Supplemental Forms and Preparations

Calcium carbonate and calcium citrate are the two most common forms of calcium found in supplements. Calcium carbonate supplements contain 40% elemental calcium, while calcium citrate contains 21% elemental calcium. Other forms of calcium supplements include calcium lactate, calcium gluconate, and calcium phosphate. Calcium supplements are available as single-entity products or in combination with vitamin D in various dosage forms including tablets, caplets, chewable tablets, and gummies.

The two primary oral forms of supplemental calcium are calcium carbonate and calcium citrate. Calcium carbonate is cheaper and more commonly used. The absorption and bioavailabilities of these two compounds differ significantly. Calcium citrate is well tolerated by subjects with achlorhydria; it is suitable for elderly patients, subjects with inflammatory bowel disease, absorption disorders, and those treated with H2-blockers or proton pump inhibitors, and it is associated with very reduced risks of kidney stones (nephrolithiasis) compared to calcium carbonate, since citrate ions inhibit crystallization. It can be freely taken at any time of the day, both in the presence and absence of food. Calcium citrate therefore represents a therapeutic alternative with fewer side effects compared to calcium carbonate.

Approximately 43% of the US population, including almost 70% of older women, use dietary supplements that contain calcium.

2. Historical and Traditional Use

While humans have consumed calcium through food since prehistory, the recognition of calcium as a distinct element, and its deliberate use in supplemental form, is relatively modern. The historical record is primarily one of calcium compounds being used in medicine and industry long before the element was isolated.

Some calcium compounds were known to the ancients, though their chemistry was unknown until the seventeenth century. Pure calcium was isolated in 1808 via electrolysis of its oxide by Humphry Davy, who named the element. Compounds such as lime (CaO, calcium oxide) were prepared by the Romans in the first century under the name calx. Literature dating back to about 975 AD notes that plaster of Paris (calcium sulphate, CaSO₄, dehydrated gypsum) is useful for setting broken bones. Other calcium compounds used in early times include limestone (CaCO₃, calcium carbonate).

According to historical sources, calcium compounds were known as early as the first century, when the ancient Romans prepared lime as calcium oxide. However, calcium sulfate (also known as plaster of Paris or lime plaster) had been known much earlier: three statues were discovered in a buried pit at 'Ain Ghazal in Jordan that were sculpted with lime plaster over armatures of reeds and twine.

Historical records reveal that societies such as the Egyptians, Greeks, and Romans incorporated calcium-rich foods into their meals, emphasizing its importance for health. These civilizations recognized the necessity of calcium for bone health and overall bodily function.

The use of calcium compounds in medicine evolved significantly from the medieval period onward. The application of calcium sulfate to set broken bones, documented around 975 AD, represents one of the earliest systematic medicinal uses of a calcium compound. The recognition of calcium as an essential dietary nutrient — and the formal establishment of dietary requirements for it — belongs to the twentieth century, particularly following the Institute of Medicine's systematic reviews of dietary reference intakes for calcium and vitamin D.

3. Key Constituents, Physiology, and Mechanisms of Action

Physiological Role and Distribution in the Body

More than 99% of the calcium in the body is stored in bone as hydroxyapatite. Calcium in this form provides skeletal strength as well as a reservoir for calcium to be released into the serum. In serum, calcium exists in three forms: protein-bound, ionized (free), and complexed (chelated). Protein-bound calcium, which accounts for 40% of the serum calcium, cannot be used by tissues. Albumin and globulin are the primary calcium-binding proteins in the serum, whereas calmodulin is the primary calcium-binding protein in the cell.

Widely involved in cell signalling, either by direct signal transduction or acting as a second messenger, calcium regulates a large range of physiological cell functions and processes including regulatory effects on many enzymes and proteins, muscle contraction, neuronal transmission and genesis, cellular motility and growth. Calcium, together with phosphate, also participates in the mineralization of calcified tissues where bones act as calcium storage site, intimately linked with the preservation of calcium balance within the non-bone tissues of the body. In order to maintain calcium at a constant level, cells have developed a complex machinery.

Calcium Signalling

The process of calcium signaling comprises a series of molecular and biophysical events that link an external stimulus to the expression of some appropriate intracellular response through an increase in cytoplasmic Ca²⁺ as a signal. The intracellular calcium signal, in nerve cells, is part of the neurotransmission mechanism. Calcium ions are responsible for stabilizing membrane potential and controlling the excitability of neurons. Calcium ions are a universal second messenger that participates in depolarizing signal transduction and contributes to synaptic activity. These ions take an active part in the mechanisms related to memory and learning.

In response to action potentials, voltage-gated calcium channels (VGCCs) open, allowing Ca²⁺ to enter into the presynaptic terminal. At the presynaptic terminal, VGCCs are activated by the incoming action potential. This allows a rapid influx of Ca²⁺ into the presynaptic membranes, subsequently triggering the fusion of neurotransmitter-filled vesicles with the presynaptic membrane.

Muscle Contraction

Calmodulin binds calcium ions and activates myosin light chain kinase to phosphorylate the myosin head, which then binds actin and causes smooth muscle contraction. Cardiac muscle is governed both by action potentials and extracellular calcium influx. The action potential triggers an inward flow of calcium that potentiates additional calcium release from the sarcoplasmic reticulum. The contraction of one cardiac muscle cell is communicated to adjacent cells through intercalated disks, thus allowing for the synchronized contraction of cardiac muscle.

Hormonal Regulation of Calcium Homeostasis

Calcitonin acts on the bones to stimulate osteoblasts to deposit calcium in bones. Calcitonin also inhibits renal reabsorption of calcium, increasing urinary calcium excretion. Finally, calcitonin also inhibits calcium absorption in the intestines. Parathyroid hormone (PTH) acts in the opposite direction — raising serum calcium — while vitamin D facilitates calcium absorption in the intestine, creating a tightly regulated endocrine axis that governs calcium balance throughout life.

Bioavailability and Absorption

Humans absorb about 30 percent of the calcium present in foods, but this varies with the type of food consumed. Bioavailability is generally increased when calcium is well solubilized and inhibited in the presence of agents that bind calcium or form insoluble calcium salts. The absorption of calcium is about 30 percent from dairy and fortified foods (e.g., orange juice, tofu, soy milk) and nearly twice as high from certain green vegetables (bok choy, broccoli, and kale). If a food contains compounds that bind calcium or otherwise interfere with calcium absorption, such as oxalic acid and phytic acid, then the food source is considered to be a poor source of calcium.

The absorption of calcium from dairy products and fortified foods is about 30%. Certain compounds in plants (e.g., oxalic acid, phytic acid) can decrease calcium absorption by forming indigestible salts with calcium. As a result, absorption of calcium is only 5% for spinach.

Calcium absorption consists of an active vitamin D-mediated component and a passive diffusional component. Approximately 40% of calcium from dairy sources is absorbed under normal circumstances, with higher absorption in children and lower absorption in the elderly. Calcium is mostly absorbed in the jejunum and low pH seems to favor its absorption, which is higher during growth, gestation/lactation and calcium and phosphorus deficiency, and lower with aging.

Foods with high levels of oxalic acid include spinach, collard greens, sweet potatoes, rhubarb, and beans. Among the foods high in phytic acid are fiber-containing whole-grain products and wheat bran, beans, seeds, nuts, and soy isolates.

4. Recommended Intakes and Reference Values

The Institute of Medicine of the National Academies established the recommendations for dietary calcium intake, with the most recent guidelines released in 2010. These recommendations were based on high-quality research studies and data gathered over the preceding decade. The Institute of Medicine committee reviewed current literature on health outcomes of calcium and vitamin D intake. They concluded that although these nutrients are crucial for maintaining bone health, their role in other health conditions is less definitive.

Based on bone health, Recommended Dietary Allowances (RDAs; covering requirements of ≥97.5% of the population) for calcium range from 700 to 1,300 mg/d for life-stage groups at least 1 year of age. For adults, the main criterion that the Food and Nutrition Board used to establish the RDAs was the amount needed to promote bone maintenance and neutral calcium balance. Calcium requirements increase to 1,200 mg for women over 50 and all adults over 70.

The effect of menopause on bone resulted in specifying different EARs and RDAs for women and men 51 to 70 years of age. After the age of 70 years, the effects of aging on bone loss resulted in EARs and RDAs that are the same for men and women.

The Tolerable Upper Intake Level (UL) — defined as the highest daily intake unlikely to cause adverse health effects — is as follows, per the Institute of Medicine and NIH ODS:

• The tolerable upper intake level for calcium ranges from 2,000 mg to 2,500 mg for adults and from 1,000 mg to 3,000 mg for infants, children, and adolescents, depending on age.
• A UL of 3,000 mg of calcium per day applies for children 9 to 13 years of age and adolescents 14 to 18 years of age.

The Tolerable Upper Intake Level (UL) is not a recommended intake. Rather, it is intended to specify the level above which the risk for harm begins to increase, and is defined as the highest average daily intake of a nutrient that is likely to pose no risk of adverse health effects for nearly all persons in the general population. As intake increases above the UL, the potential risk for adverse effects increases.

Daily doses of 1,000 to 1,200 mg of calcium combined with vitamin D have shown modest benefits in reducing fractures. Exceeding the recommended amounts has not demonstrated additional benefits.

5. Scientific Evidence by Area of Use

5.1 Bone Health and Osteoporosis Prevention

Evidence Level: Moderate to strong for skeletal outcomes in specific populations; weak to absent for fracture prevention in community-dwelling adults.

The Institute of Medicine's Committee concluded that available scientific evidence supports a key role of calcium and vitamin D in skeletal health, consistent with a cause-and-effect relationship and providing a sound basis for determination of intake requirements. For extraskeletal outcomes, including cancer, cardiovascular disease, diabetes, and autoimmune disorders, the evidence was inconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.

FDA has approved a health claim for the use of supplements containing calcium and vitamin D to reduce the risk of osteoporosis. However, not all research supports this claim. Despite the importance of calcium in bone health, observational evidence is mixed on the link between calcium intakes and measures of bone strength in older adults.

There is now a large body of trial evidence demonstrating that calcium supplements do not prevent fractures in community-dwelling adults. They commonly produce gastrointestinal side effects, sometimes serious, and increase other health risks.

Numerous recent systematic reviews have concluded that there is no evidence for associations between calcium supplements and reduced risk of fracture or improvement of bone density in people aged over 50 years.

In younger populations, the picture differs. A systematic review and meta-analysis of randomized clinical trials assessed the effects of calcium supplementation on bone mineral density (BMD) or bone mineral content (BMC) in people under 35 years old and identified 43 studies involving 7,382 subjects. Since calcium supplements are unlikely to translate into clinically meaningful reductions in fractures or improvement of bone mass in aged people, researchers have explored whether it is possible to increase bone mass at peak by administering calcium supplements before the age of reaching peak bone mass or at the plateau of this peak to prevent osteoporosis and reduce the risk of fractures in later life.

Regarding postmenopausal women undergoing pharmacological treatment for osteoporosis, data from 37 RCTs (43,397 patients) were retrieved in one major systematic review. Meta-analyses of RCTs reported only a weak effect on the occurrence of fractures and have drawn attention to possible side effects of calcium supplements previously ignored. The role of calcium and vitamin D supplementation in the management of osteoporosis remains controversial.

The U.S. Preventive Services Task Force reviewed this area comprehensively: The USPSTF found 19 randomized clinical trials (RCTs) that reported on fracture, fall, or all-cause mortality outcomes with vitamin D or calcium supplementation, or both, over 9 months to 7 years of followup. The review excluded studies conducted in populations with a known disorder related to bone metabolism (e.g., osteoporosis or vitamin D deficiency) or taking medication known to be associated with osteoporosis.

Some research suggests that calcium supplements with or without vitamin D increase bone mineral density in older adults, but others do not. In addition, it is not clear whether calcium supplements help prevent fractures.

5.2 Cardiovascular Disease Risk

Evidence Level: Mixed, with some RCT-based meta-analyses suggesting increased risk; evidence is controversial and actively debated.

Results from epidemiological studies and a meta-analysis of randomized, controlled clinical trials, including a subgroup analysis from the Women's Health Initiative, have prompted concern about a potential association between calcium supplement use and a small increase in the risk of adverse cardiovascular events.

A total of 13 double-blind, placebo-controlled RCTs (28,935 participants in an intervention group and 14,243 in a control group) were included in one meta-analysis. Calcium supplements significantly increased the risk of CVD (RR 1.15, 95% CI 1.06–1.25) and coronary heart disease (CHD) (RR 1.16, 95% CI 1.05–1.28) specifically in healthy postmenopausal women. In the subgroup meta-analysis, dietary calcium intake of 700–1,000 mg per day or supplementary calcium intake of 1,000 mg per day significantly increased the risk of CVD and CHD. This meta-analysis found that calcium supplements increased risk of CVD by about 15% in healthy postmenopausal women.

However, a number of issues with the studies, such as inadequate compliance with the intervention, use of nontrial calcium supplements, potential bias in event ascertainment, and lack of information on and adjustment for known cardiovascular risk determinants, suggest that bias and confounding may partly explain these findings.

According to the NIH ODS, calcium supplements have the potential to increase the risk of cardiovascular disease, according to some research. The evidence remains a subject of active scientific discussion, and the NIH has not issued a definitive recommendation against calcium supplementation on cardiovascular grounds.

5.3 Hypertension and Blood Pressure

Evidence Level: Modest, with some benefit suggested from dietary calcium; supplemental calcium effects are less clear.

Calcium may slightly adjust lipid profiles and reduce blood pressure and — more importantly — the risk of developing hypertension. In prospective studies, the risks for developing hypertension were reduced with calcium supplementation.

5.4 Preeclampsia and Hypertensive Disorders of Pregnancy

Evidence Level: Mixed; earlier evidence suggested benefit at high doses in low-intake populations; the most recent large-trial evidence is less supportive.

A Cochrane review showed that high-dose (≥1,000 mg per day) calcium supplementation during pregnancy reduced the risk of preeclampsia (8 trials, 10,678 women: average RR 0.36, 95% CI 0.20 to 0.65; I²=76%). But the quality was graded low due to significant heterogeneity.

However, more recent evidence has challenged these findings. An updated Cochrane review has found that calcium supplementation has no effect on preeclampsia, challenging long-held assumptions about the role of calcium in preventing hypertensive disorders in pregnancy. Researchers from Stellenbosch University found strong evidence from large trials that calcium supplementation during pregnancy does not reduce the risk of preeclampsia.

Evidence from 6 studies (15,364 women) showed that calcium may make little to no difference to preeclampsia compared to placebo. When analysing only large studies with more than 500 women (4 studies, 14,730 women), there was strong evidence confirming that calcium makes little to no difference to preeclampsia compared to placebo. Calcium probably results in little to no difference in the overall risk of a mother dying or developing severe complications of preeclampsia.

Calcium supplementation has long been considered a potential preventive measure, especially in settings with low calcium intake. Current World Health Organization (WHO) guidelines recommend daily calcium supplementation in such populations. However, evidence supporting this approach has always been mixed, and more recent reviews raise further doubts.

5.5 Colorectal Cancer and Adenomas

Evidence Level: Preliminary; some evidence of reduced adenoma recurrence; no confirmed effect on colorectal cancer incidence or mortality.

Earlier clinical trial data had suggested a potential protective role for calcium against colorectal adenoma recurrence. The NIH ODS notes that the evidence from trials examining the combination of calcium plus vitamin D supplementation and colorectal cancer outcomes has not been definitive. Some research suggests that high calcium intakes might increase the risk of heart disease and prostate cancer. Any protective role against colorectal neoplasm remains under investigation and cannot be confirmed as established based on the available human clinical trial record.

5.6 Weight Management

Evidence Level: Weak and inconsistent; clinical trials have not confirmed a meaningful effect.

Clinical trials and meta-analyses of RCTs assessing the impact of calcium supplements or increased intakes of calcium from dairy products on prevention of weight gain or promotion of fat loss or weight loss have had mixed results. For example, postmenopausal women who took 1,000 mg calcium and 400 IU vitamin D daily for 3 years in the Women's Health Initiative (WHI) and whose daily intakes were less than 1,200 mg calcium at baseline were 11% less likely to gain 1 kg of weight or more than those who took placebo during this period.

A systematic review and meta-analysis of 41 RCTs that examined the effect of dairy foods or calcium supplements (≥300 mg/day) in 4,802 adults found that higher calcium intakes from dairy foods had no impact on body weight or body fat, although they did reduce body fat when combined with an energy-restricted diet. In addition, calcium supplements had no effect on body weight or body fat.

Research hasn't clearly shown whether calcium from dairy products or supplements helps you lose weight or prevents weight gain. Some studies show that consuming more calcium helps, but other studies do not.

5.7 Metabolic Syndrome

Evidence Level: Preliminary; limited human data.

Some research suggests that a higher intake of calcium might help lower the risk of metabolic syndrome in women but not men. More studies are needed.

5.8 Hypocalcemia and Hypoparathyroidism

Evidence Level: Well-established clinical use.

Calcium supplements are considered a standard treatment for hypocalcemia associated with postsurgical hypoparathyroidism and achieves better clinical results. This represents one of the most clearly evidence-supported pharmacological uses of calcium supplementation.

6. Body Systems Associated with Calcium

• Skeletal system: Dietary calcium is crucial in bone health and metabolism. In young patients, adequate vitamin D and calcium intake are critical for bone growth, established around age 30. Adequate bone health reduces the risk of developing osteoporosis and subsequent pathological fractures in adulthood.
• Cardiovascular system: Cardiac muscle is governed both by action potentials and extracellular calcium influx. The action potential triggers an inward flow of calcium that potentiates additional calcium release from the sarcoplasmic reticulum. The contraction of one cardiac muscle cell is communicated to adjacent cells through intercalated disks, thus allowing for the synchronized contraction of cardiac muscle.
• Nervous system: Calcium ions play a key role in the physiological processes of the central nervous system. The intracellular calcium signal in nerve cells is part of the neurotransmission mechanism. They are responsible for stabilizing membrane potential and controlling the excitability of neurons.
• Muscular system: Calcium is essential for both skeletal and smooth muscle contraction, operating via calmodulin-dependent activation of myosin light-chain kinase pathways.
• Endocrine/hormonal system: Calcium participates in the secretion of hormones and neurotransmitters, as well as being regulated by the parathyroid-vitamin D-calcitonin axis.
• Renal system: The kidneys play a central role in calcium excretion and conservation, and excess supplemental intake has been associated with increased risk of kidney stones.

7. Dosage Forms and Dosages Reported in Studies

The following dosages appear in cited clinical sources:

• Daily doses of 1,000 to 1,200 mg of calcium combined with vitamin D have shown modest benefits in reducing fractures in some trials.
• Postmenopausal women in the Women's Health Initiative received 1,000 mg calcium and 400 IU (10 mcg) vitamin D daily for 3 years.
• High-dose calcium supplementation (≥1,000 mg per day) was used in pregnancy trials examining preeclampsia prevention.
• Calcium supplement doses of ≥300 mg/day were assessed in a systematic review and meta-analysis of 41 RCTs in adults.
• Calcium carbonate at 1,200 mg/day was used in a 5-year, double-blind, placebo-controlled study examining gastrointestinal adverse events.
• Women younger than 19 should consume 1,300 mg of calcium daily during pregnancy and lactation. For women older than 19, the RDA of 1,000 mg aligns with the general population's RDA.

Regarding supplement forms: calcium carbonate is only 40% elemental calcium, so 1,250 milligrams of calcium carbonate contains 500 milligrams of elemental calcium. The elemental calcium content is the clinically relevant dose figure.

8. Safety Considerations and Notable Interactions

Gastrointestinal Effects

Calcium supplements may increase the incidence of constipation, severe diarrhea, and abdominal pain. Calcium carbonate is more often associated with gastrointestinal side effects, including constipation, flatulence, and bloating.

Kidney Stones

Higher intakes of supplemental calcium might increase the risk of kidney stones. Prolonged intake of calcium carbonate is often associated with the onset of kidney stones (nephrolithiasis). Calcium citrate carries a comparatively lower lithogenic risk due to citrate's inhibitory effect on crystal formation.

Cardiovascular Risk

According to some research, calcium supplements have the potential to increase the risk of cardiovascular disease. As described in Section 5.2, a meta-analysis of 13 RCTs found approximately a 15% increase in CVD risk in healthy postmenopausal women, though methodological limitations in the underlying studies temper these conclusions.

Hypercalcemia and Toxicity

High levels of calcium in the blood and urine can cause poor muscle tone, poor kidney function, low phosphate levels, constipation, nausea, weight loss, extreme tiredness, frequent need to urinate, abnormal heart rhythms, and a high risk of death from heart disease. A condition called milk-alkali syndrome, hypercalcemia almost always caused by excessive use of calcium supplements, can lead to kidney failure that requires dialysis.

Prostate Cancer Risk

Higher calcium intakes might also increase the risk of prostate cancer. This association has been observed in some observational and supplementation trial data, although the causal pathway has not been definitively established.

Drug Interactions

Calcium supplements may interact with medications, and some medications may affect calcium levels. These medications include dolutegravir, levothyroxine, lithium, and quinolone antibiotics. Calcium supplements have the potential to interact with certain medications, and several types of medications might adversely affect calcium levels.

The interaction with levothyroxine (thyroid hormone replacement) and quinolone/tetracycline antibiotics is particularly well-documented: calcium can chelate these drugs and reduce their gastrointestinal absorption, thereby potentially reducing their efficacy if taken concurrently. Administration timing (i.e., separation of doses by several hours) is typically used to manage this interaction in clinical practice.

Vitamin D Dependency

Vitamin D and magnesium help the body better absorb calcium. In the absence of adequate vitamin D, calcium absorption from both dietary sources and supplements is significantly diminished, which is why calcium and vitamin D are frequently studied and recommended together.

References

• NIH Office of Dietary Supplements – Calcium: Health Professional Fact Sheet
• NIH Office of Dietary Supplements – Calcium: Consumer Fact Sheet
• StatPearls (NIH/NCBI): Dietary Calcium and Supplementation – Plantz MA, Bittar K
• StatPearls (NIH/NCBI): Physiology, Calcium
• Institute of Medicine / National Academies: Dietary Reference Intakes for Adequacy – Calcium and Vitamin D (NCBI Bookshelf)
• Institute of Medicine / National Academies: Tolerable Upper Intake Levels – Calcium and Vitamin D (NCBI Bookshelf)
• Institute of Medicine / National Academies: Summary – Dietary Reference Intakes for Calcium and Vitamin D (NCBI Bookshelf)
• Ross AC et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the IOM: What Clinicians Need to Know. J Clin Endocrinol Metab. 2011;96(1):53–58. PMC3046611
• PMC: Calcium: An Overview From Physiology to Pathological Mineralization (Editorial). PMC9263913
• NIH/NCBI Basic Neurochemistry: Ca2+ Signaling. NBK27950
• Calcium Ions in the Physiology and Pathology of the Central Nervous System. PMC11642227
• Signaling in Muscle Contraction. PMC4315934
• Effects of Calcium Supplementation on the Risk of Fracture in Older Adults (meta-analysis). PMC12599811
• Reid IR et al. Calcium Supplementation – Efficacy and Safety. Current Osteoporosis Reports. 2025.
• Liu et al. The effect of calcium supplementation in people under 35 years old: A systematic review and meta-analysis. eLife. 2022;11:e79002
• Effects of calcium supplementation on the prevention of preeclampsia: an umbrella review of systematic reviews and meta-analyses. PMC11922079
• Cochrane: New evidence questions the benefit of calcium supplements in pregnancy for preventing pre-eclampsia (2025 update)
• A Review of Calcium Supplements and Cardiovascular Disease Risk. Advances in Nutrition. PMC3648700
• Calcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials. Nutrients. 2021;13(2):368. PMC7910980
• The good, the bad, and the ugly of calcium supplementation: a review of calcium intake on human health. PMC6276611
• Overview of Calcium – Dietary Reference Intakes for Calcium and Vitamin D. NCBI Bookshelf NBK56060
• Bioavailability of Micronutrients from Nutrient-Dense Whole Foods: Zooming in on Dairy, Vegetables, and Fruits. Frontiers in Nutrition. 2020
• Calcium Absorption from Food Products: Food Matrix Effects. PMC8746734
• Calcium orthophosphates and human beings: A historical perspective from the 1770s until 1940. PMC3549858
• Britannica: Calcium – Definition, Properties, & Compounds
• WebElements: Calcium – Historical Information
• U.S. Preventive Services Task Force: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Falls and Fractures in Community-Dwelling Adults
• Frontiers in Medicine: Effects of calcium supplementation on the prevention of preeclampsia (umbrella review, 2025)